Figure 7.
FST overexpression alleviated hepatic steatosis in HFD mice. (A) Hepatic FST mRNA expression in the control (treated with an AAV vector encoding GFP) and FST-overexpressing (treated with an AAV vector encoding FST288 and FST315) HFD mice. (B) Body weight of the control and FST-overexpressing HFD mice. (C and D) H&E and oil red O staining in the liver sections of the control and FST-overexpressing HFD mice. (200×, scale bar=100 µm). The marks represented the main pathohistological difference. (E–L) The serum levels of T-CHO, TG, glucose, ALT, AST, FST, insulin, and C-peptide in the control and FST-overexpressing HFD mice.
Notes: n= 5. *P< 0.05, **P< 0.01, ****P< 0.0001 vs GFP group.
Abbreviations: FST, follistatin; ORO, oil red O; AAV, adeno-associated virus; T-CHO, total cholesterol; TG, triglyceride; ALT alanine aminotransferase; AST, aspartate aminotransferase.